Nan Mou
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
Journal: Cell transplantation
Published: March 07, 2023
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.
Journal: Frontiers in immunology
Published: February 08, 2023
Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
Journal: Annals of hematology
Published: January 31, 2023
Activity comparison of humanized CD19 CAR-T cells with murine CD19 CAR-T on Nalm-6 cells and xenograft tumor model
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: August 18, 2021
Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk.
Journal: Frontiers in oncology
Published: May 06, 2021
Overexpression of NKG2D-CD3ζ in NY-ESO-1 TCR-T cells enhanced cytotoxicity to acute myeloid leukemia cells in vitro
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 17, 2020
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant.
Journal: Frontiers in oncology
Published: July 01, 2020
Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.
Journal: Hematological oncology
Published: March 28, 2020
Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
Journal: British journal of haematology
Published: December 24, 2019
Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy.
Journal: Oncology letters
Published: July 08, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026